SCHEMBL1403616

SCHEMBL1403616

OCCc1ccc(-c2cc[c]c(CCO)c2-c2cccc(CCO)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACMSD Q8TDX5 1/20 0.41
MAP4K4 O95819 1/20 0.38
FFAR1 O14842 4/20 0.37
TDP1 Q9NUW8 1/20 0.37
CDK8 P49336 1/20 0.35
CYP4F2 P78329 2/20 0.33
CYP4A11 Q02928 2/20 0.33
BACE1 P56817 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
ALOX5 P09917 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
HTR7 P34969 2/20 0.33
CA2 P00918 1/20 0.33
RIPK1 Q13546 1/20 0.32
PDE4B Q07343 1/20 0.31
HTR1A P08908 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8477404 0.79 TDP1 (0.38) TDP1BACE1ALDH1A1MAPT
SCHEMBL8474671 0.73 BACE1 (0.33) BACE1
SCHEMBL8480981 0.70 PTGS2 (0.46) BACE1KDM4E
SCHEMBL8477428 0.69 PTGS2 (0.40) FFAR1KDM4EALDH1A1MAPTPDE4B
SCHEMBL2571534 0.67 TAAR1 (0.55) ACMSDMAP4K4TDP1CDK8BACE1
SCHEMBL11040917 0.66 CALM1 (0.38) TDP1ALDH1A1MAPT
SCHEMBL5865105 0.66 TDP1 (0.62) ACMSDMAP4K4FFAR1TDP1CDK8
SCHEMBL7464716 0.66 GCGR (0.38) KDM4EALDH1A1MAPT
SCHEMBL8473979 0.65 DHFR (0.34) KDM4EALDH1A1MAPT
SCHEMBL239199 0.65 TDP1 (0.65) ACMSDMAP4K4TDP1CDK8CYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2297085-A2 SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS Allergan, Inc. (US) 2011-03-23 EP disclosed
EP-2291353-A1 THERAPEUTIC PROSTAGLANDIN COMPOUNDS USED AS OCULAR HYPOTENSIVE AGENTS Allergan, Inc. (US) 2011-03-09 EP disclosed
WO-2009142967-A1 THERAPEUTIC PROSTAGLANDIN COMPOUNDS USED AS OCULAR HYPOTENSIVE AGENTS ALLERGAN, INC. (US) 2009-11-26 WO disclosed
WO-2009137411-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2009-11-12 WO disclosed
EP-2114875-A1 SUBSTITUTED ARYLCYLOPENTENES AS THERAPEUTIC AGENTS Allergan, Inc. (US) 2009-11-11 EP disclosed
WO-2009132093-A2 SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2009-10-29 WO disclosed
EP-2069295-A2 SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS Allergan, Inc. (US) 2009-06-17 EP disclosed
EP-2066615-A2 CYCLOPENTANE DERIVATIVES AS ANTIGLAUCOMA AGENTS Allergan, Inc. (US) 2009-06-10 EP disclosed
EP-2046714-A2 THERAPEUTIC COMPOUNDS Allergan, Inc. (US) 2009-04-15 EP disclosed
EP-2043993-A2 CYCLOPENTANE DERIVATIVES AS ANTIGLAUCOMA AGENTS Allergan, Inc. (US) 2009-04-08 EP disclosed
WO-2008091810-A1 SUBSTITUTED ARYLCYLOPENTENES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2008-07-31 WO disclosed
WO-2008008700-A2 SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2008-01-17 WO disclosed
WO-2008008701-A2 SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2008-01-17 WO disclosed
WO-2008008660-A2 CYCLOPENTANE DERIVATIVES AS ANTIGLAUCOMA AGENTS ALLERGAN, INC. (US) 2008-01-17 WO disclosed
WO-2008008718-A2 CYCLOPENTANE DERIVATIVES AS ANTIGLAUCOMA AGENTS ALLERGAN, INC. (US) 2008-01-17 WO disclosed
WO-2007149829-A2 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2007-12-27 WO disclosed